Thermo Fisher Scientific Inc. reported strong financial results for the fourth quarter and full year ended December 31, 2024. For Q4 2024, revenue grew 5% to $11.40 billion, surpassing analyst estimates of $11.28 billion. Organic revenue growth was 4%, and Core organic revenue growth was 5%, reflecting robust demand for its products and services.
The company's adjusted diluted EPS for the fourth quarter was $6.10, exceeding Wall Street expectations of $5.94, and an increase from $5.67 in the same quarter of 2023. GAAP diluted EPS for Q4 2024 was $4.78, up from $4.20 year-over-year, while adjusted operating income reached $2.72 billion, compared with $2.55 billion in the prior year.
For the full year 2024, total revenue was $42.88 billion, flat compared to 2023, with organic and Core organic revenue growth also flat. Full-year adjusted EPS was $21.86, an increase from $21.55 in 2023. The company stated it would provide its 2025 financial guidance during its earnings conference call.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.